Global Pertuzumab Market Size By Type (Human Source, Animal Source), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Pertuzumab Market was valued at USD 6.3 billion in 2023 and is projected to reach USD 10.4 billion by 2031, expanding at a CAGR of 6.5% during the forecast period (2023–2031). The rising global incidence of HER2-positive breast cancer and the increasing preference for targeted therapies are key drivers of market growth. Pertuzumab, a monoclonal antibody that inhibits HER2 receptor dimerization, is widely used in combination regimens to improve outcomes in both metastatic and early-stage breast cancer. Regulatory approvals and inclusion in clinical treatment guidelines across multiple regions are expected to sustain market momentum in the coming years.

Drivers:

1. Increasing Prevalence of HER2-Positive Breast Cancer:

The growing number of HER2-positive breast cancer diagnoses worldwide, especially among women aged 40–60, is directly contributing to the rising demand for pertuzumab-based therapies.

2. Rising Adoption of Targeted Therapies:

With healthcare systems moving towards precision medicine, targeted drugs like pertuzumab are gaining significant traction due to their efficacy and lower toxicity profiles compared to traditional chemotherapy.

3. Expanded Indications and Regulatory Approvals:

Pertuzumab has received approvals for various treatment settings, including neoadjuvant and metastatic stages. Ongoing clinical trials aiming at expanding indications (e.g., gastric cancer) present further growth potential.

Restraints:

1. High Treatment Costs:

Despite clinical efficacy, the high cost of pertuzumab therapy can limit access in low- and middle-income countries, affecting market penetration.

2. Biosimilar Competition:

Patent expirations in the forecast period could lead to biosimilar introductions, potentially impacting branded sales.

Opportunity:

1. Market Expansion in Emerging Economies:

The increasing focus on oncology treatment infrastructure in Asia-Pacific and Latin America offers lucrative opportunities for pertuzumab manufacturers, especially through public-private healthcare initiatives.

2. Clinical Pipeline and Combination Therapies:

Combination regimens involving pertuzumab and novel immunotherapies or other monoclonal antibodies are under investigation, which may offer additional treatment options and market expansion.

Market by System Type Insights:

By Dosage Form, the intravenous (IV) formulation dominated the global pertuzumab market in 2023, due to its established use in hospitals and infusion centers. However, subcutaneous (SC) delivery formats under development are expected to gain market share by improving patient convenience and reducing administration time.

Market by End-Use Insights:

Hospitals accounted for the largest end-use segment in 2023, followed by cancer specialty clinics. The high volume of inpatient and outpatient chemotherapy treatments conducted in hospitals is a major contributor to this dominance. Specialty clinics are expected to witness rapid growth, driven by decentralization of oncology care and rise in ambulatory infusion centers.

Market by Regional Insights:

North America held the largest share of the pertuzumab market in 2023, supported by strong healthcare infrastructure, favorable reimbursement policies, and the high prevalence of HER2-positive breast cancer. Asia-Pacific is expected to be the fastest-growing region due to increasing cancer incidence rates, rising awareness, and healthcare reforms aimed at expanding oncology treatment access.

Competitive Scenario:

Key players in the global pertuzumab market include:

Genentech, Inc. (a member of the Roche Group)

Mylan N.V.

Pfizer Inc.

Samsung Bioepis Co., Ltd.

Amgen Inc.

These companies focus on strategic collaborations, clinical trials, regulatory approvals, and biosimilar development to strengthen their market presence. For instance:

In 2024, Roche announced a Phase III trial evaluating pertuzumab in combination with immunotherapy for HER2-low metastatic breast cancer.

Mylan initiated biosimilar development in 2023 targeting pertuzumab's formulation patent expiry in major markets.

Scope of Work – Global Pertuzumab Market

Key Market Developments:

August 2023: Roche received extended FDA approval for pertuzumab in combination with trastuzumab and docetaxel for the treatment of early-stage HER2-positive breast cancer.

March 2024: Samsung Bioepis announced preclinical success of its pertuzumab biosimilar and plans to file for global regulatory approval by 2026.

January 2025: Pfizer entered a research agreement with a leading oncology institute to evaluate pertuzumab in HER2-mutated gastric cancer.

FAQs:

1) What is the current market size of the Global Pertuzumab Market?

The market size was USD 6.3 billion in 2023.

2) What is the major growth driver of the Global Pertuzumab Market?

The primary growth driver is the increasing incidence of HER2-positive breast cancer and the adoption of targeted therapies.

3) Which is the largest region during the forecast period in the Global Pertuzumab Market?

North America remains the largest region, with Asia-Pacific projected to grow fastest.

4) Which segment accounted for the largest market share in the Global Pertuzumab Market?

The IV dosage form and hospital end-use segments held the largest market shares in 2023.

5) Who are the key market players in the Global Pertuzumab Market?

Key players include Genentech (Roche), Pfizer Inc., Mylan N.V., Samsung Bioepis, and Amgen Inc.